TABLE 4.
HR of invasive ventilation/death from fitting a marginal Cox regression model.
| Unadjusted and adjusted marginal relative hazards of invasive ventilation/death | |||||
|---|---|---|---|---|---|
| Unadjusted HR (95% CI) | p-value | Adjusted a HR (95% CI) | p-value | ||
| All patients | |||||
| SoC | 1.00 | 1.00 | |||
| LPV/r + HCQ | 1.01 (0.61, 1.66) | 0.972 | 1.09 (0.60, 1.98) | 0.772 | |
| HCQ | 0.78 (0.42, 1.44) | 0.423 | 0.81 (0.38, 1.72) | 0.584 | |
| LPV/r | 1.42 (0.83, 2.45) | 0.201 | 1.55 (0.82, 2.93) | 0.173 | |
| Baseline PaO2/FiO2 0–300 | |||||
| SoC | 1.00 | 1.00 | |||
| LPV/r + HCQ | 0.51 (0.24, 1.08) | 1.41 (0.37, 5.33) | |||
| HCQ | 0.53 (0.22, 1.30) | 1.48 (0.35, 6.18) | |||
| LPV/r | 0.89 (0.41, 1.94) | 2.48 (0.65, 9.43) | |||
| p-value for interaction | |||||
| <0.001 | |||||
| Baseline PaO2/FiO2 > 300 | |||||
| SoC | 1.00 | 1.00 | |||
| LPV/r + HCQ | 1.57 (0.59, 4.17) | 1.63 (0.56, 4.78) | |||
| HCQ | 0.87 (0.25, 3.00) | 0.83 (0.22, 3.18) | |||
| LPV/r | 0.67 (0.13, 3.42) | 0.73 (0.14, 3.95) | |||
a
Adjusted for age, gender, presence of comorbidities, duration of symptoms and time-varying use of immunomodulatory drugs, azithromycin, steroids, anticoagulants, and censoring using IPW.
NB. The stratified analysis is based on the subset of 396/590 (67%) participants with available PaO2/FiO2 values at baseline.